Anthem Biosciences shares rose 2.36% to Rs 802.95 on July 31, 2026, following a strong fiscal year. The company reported a significant revenue increase to Rs 2,124 Crore and maintains a very low debt level. Investors are now balancing this annual growth against a recent dip in quarterly earnings.
Anthem Biosciences shares traded at Rs 802.95 on the NSE during the session on July 31, 2026, marking a 2.36% gain. The stock is a component of the Nifty Midcap 150 index. This move follows the company’s recent annual financial report, which showed significant growth compared to previous years.
Annual Financial Growth vs. Quarterly Trends
The company reported a major increase in its annual financial performance. Revenue reached Rs 2,124.33 Crore for the year ending March 2026, a 101% rise from Rs 1,056.92 Crore in March 2023. During the same three-year period, net profit grew by 53.6%, moving from Rs 385.19 Crore to Rs 591.79 Crore.
While the yearly trend is positive, the company’s recent June 2026 quarterly results showed a contraction. Revenue for the quarter stood at Rs 418.22 Crore with a net profit of Rs 119.94 Crore. This is lower than the figures recorded in the June 2025 quarter, where the company generated Rs 540.21 Crore in revenue and Rs 135.79 Crore in net profit. Investors may track whether this quarterly dip is a temporary seasonal issue or a sign of slowing demand in the contract research or manufacturing sector.
Balance Sheet and Cash Generation
One of the company's notable financial features is its balance sheet strength. The debt-to-equity ratio sits at 0.02, indicating that the company relies very little on borrowings to fund its operations. This is often viewed as a sign of financial stability in capital-intensive sectors like pharmaceuticals or biotechnology.
Furthermore, the company has shown a substantial improvement in its ability to generate cash. Cash flow from operations for the year ending March 2026 was Rs 844 Crore, up significantly from Rs 305 Crore in March 2023. Total assets also expanded to Rs 3,429 Crore by the end of March 2026, supported by reserves and surplus of Rs 2,930 Crore.
Looking ahead, the primary monitorable for shareholders will be the trend in quarterly profitability. While the long-term annual trajectory remains strong, market participants often look for consistent performance across quarters to gauge the sustainability of growth. Future updates regarding the company’s order book or new client acquisitions could provide more clarity on its ability to reverse the recent quarterly profit decline.